Arcturus Therapeutics Holdings Inc. ARCT
Set alert
At close · Oct 30
After hours · Oct 30, 6:12 PM ET
- YTD
- +79.93%
- 1 year
- +14.54%
- Open
- 11.81
- Prev close
- 12.15
- Mkt cap
- 313.51M
- Vol
- 1.85M
- Avg vol
- 967.36K
- EPS
- -3.33
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 10.58
- High
- 11.93
- Forward P/E
- -7.41
- Beta
- 2.64
- Short ratio
- 9.41
- Inst. own
- 90.16%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 18.22
- 200-d avg
- 24.44
- 1y target
- 79.47
5D chart
Signals (96)
| Name | Time | Ago |
|---|---|---|
| RSI: Oversold | Oct 30, 10:00 AM | 2 days ago |
| RSI: Oversold | Oct 30, 9:45 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 9:30 AM | 2 days ago |
| RSI: Oversold | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bullish | Oct 29, 3:30 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:20 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:10 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:05 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:50 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 2:35 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:20 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:20 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:15 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:30 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 12:30 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 12:25 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:40 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:40 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:35 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:35 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:25 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:20 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:00 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:55 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:45 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:00 AM | 3 days ago |
| SMA: Bearish | Oct 29, 9:55 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:55 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:50 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:45 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:40 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:40 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 2:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:20 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:15 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:10 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:05 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:55 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 1:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:45 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:20 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:30 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:10 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 4 days ago |
| RSI: Overbought | Oct 28, 10:35 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:20 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:20 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 10:15 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 9:40 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 27, 3:35 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:30 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:25 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:20 PM | 5 days ago |
| RSI: Overbought | Oct 27, 3:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:20 PM | 5 days ago |
| RSI: Overbought | Oct 27, 2:10 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 1:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 12:30 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 12:25 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 12:15 PM | 5 days ago |
| RSI: Overbought | Oct 27, 12:15 PM | 5 days ago |
| RSI: Overbought | Oct 27, 11:40 AM | 5 days ago |
| RSI: Overbought | Oct 27, 11:15 AM | 5 days ago |
| RSI: Overbought | Oct 27, 10:30 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:55 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 9:40 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:35 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 9:30 AM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:50 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 3:20 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:55 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 2:00 PM | 6 days ago |
| SMA: Bearish | Oct 26, 11:30 AM | 6 days ago |
| SMA: Bullish | Oct 26, 10:50 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:30 AM | 6 days ago |
News
5 days ago businesswire.com
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 5, 2026
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and…
2 weeks ago benzinga.com
Transcript: Arcturus Therapeutics Q2 2026 Earnings Conference Call
Arcturus Therapeutics (NASDAQ:ARCT) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This content is powered by Benzinga APIs.…
3 weeks ago benzinga.com
Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday
U.S. stocks rose Friday; Humana jumped 12.3% after improved 2027 Medicare Advantage ratings and reaffirmed FY26 EPS guidance.
3 weeks ago benzinga.com
CrowdStrike To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Friday
Analysts raised targets for HOOD, SAIL, U and CRWD; cut targets for BULL, ALGN and PCRX, with PCRX downgraded to Neutral.
-
3 weeks ago benzinga.com
Leerink Partners Maintains Outperform on Arcturus Therapeutics, Raises Price Target to $19
Leerink Partners analyst Lili Nsongo maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Outperform and raises the price target from $13 to $19.
1 month ago zacks.com
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
RNA therapeutics are gaining momentum as Alnylam, Ionis, Wave Life Sciences and Arcturus advance innovative treatments targeting a range of diseases.
1 month ago marketbeat.com
Arcturus Highlights ARCT-810 Phase II Data, Unveils Next-Gen OTC Therapy Platform
Arcturus Therapeutics NASDAQ: ARCT presented preliminary Phase II data for ARCT-810, its mRNA therapeutic candidate for ornithine transcarbamylase, or OTC, deficiency, while outlining plans to…
1 month ago benzinga.com
Why Is Arcturus Therapeutics Stock Gaining Thursday?
Arcturus Therapeutics (ARCT) surged over 6% after sharing positive Phase 2 interim data for its OTC deficiency drug, ARCT-810.
-
1 month ago benzinga.com
Citigroup Upgrades Arcturus Therapeutics to Buy, Raises Price Target to $20
Citigroup analyst Yigal Nochomovitz upgrades Arcturus Therapeutics (NASDAQ:ARCT) from Neutral to Buy and raises the price target from $8 to $20.
1 month ago benzinga.com
Everpure, Fervo Energy, Charles River Laboratories And Other Big Stocks Moving Higher On Thursday
Nasdaq fell 150+ points, while Everpure jumped 14% after unveiling growth plans and a FY2028 outlook; other stocks also gained.
-
1 month ago benzinga.com
BTIG Maintains Buy on Arcturus Therapeutics, Lowers Price Target to $20
BTIG analyst Thomas Shrader maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and lowers the price target from $23 to $20.
1 month ago benzinga.com
Why GlucoTrack Shares Are Trading Higher By Around 118%; Here Are 20 Stocks Moving Premarket
GlucoTrack surged 117.7% premarket after Lokahi Therapeutics signed its first external partnership; other stocks saw notable gains and losses.
1 month ago seekingalpha.com
Arcturus Therapeutics Holdings Inc. (ARCT) Discusses Phase II Data for OTC Deficiency and Advances in mRNA Liver Therapeutics Platform Transcript
Arcturus Therapeutics Holdings Inc. (ARCT) Discusses Phase II Data for OTC Deficiency and Advances in mRNA Liver Therapeutics Platform Transcript
-
1 month ago benzinga.com
Arcturus Therapeutics Says ARCT-810 Generally Safe And Well Tolerated, Demonstrating Encouraging Activity Across Key Urea Cycle Biomarkers In Ongoing Phase 2 Study
Arcturus Therapeutics Holdings Inc. ((the "Company, " "Arcturus, NASDAQ:ARCT), a messenger RNA medicines company focused on the development of liver and respiratory therapeutics, today announced…
-
1 month ago benzinga.com
Arcturus To Acquire myNEO, An AI Discovery Company, To Improve mRNA Design Quality, Accelerate Innovation, And Enhance Target Identification Capability; No Financial Terms Disclosed; Co To Host Presentation At 4:30 p.m. ET today
Arcturus to Acquire myNEOArcturus has entered into a definitive agreement to acquire myNEO, subject to customary closing conditions. The transaction is expected to close in October. Arcturus has been…
-
1 month ago benzinga.com
Arcturus Therapeutics Announces Interim Phase 2 Results From ARCT-810 In OTC Deficienc And Introduces LUNAR 2.0
ARCT-810 generally safe and well tolerated, demonstrating encouraging activity across key urea cycle biomarkers in ongoing Phase 2 studyLUNAR 2.0™ produces greater than 30-fold higher protein…
1 month ago businesswire.com
Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company,” “Arcturus,” Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and…
1 month ago seekingalpha.com
Arcturus Therapeutics: A Speculative Buy For Their OTC Deficiency Program
Arcturus Therapeutics is advancing mRNA-based therapies, with ARCT-810 for OTC deficiency as a near-term catalyst and ARCT-032 for cystic fibrosis in phase 2. ARCT-810 has shown promising phase 2…
1 month ago gurufocus.com
Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform
Arcturus Therapeutics Holdings Inc. (the âCompanyâ, âArcturusâ, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and
-
1 month ago benzinga.com
Arcturus Therapeutics To Present Overview Of ARCT-810 Phase 2 Clinical Program For Ornithine Transcarbamylase Deficiency And Arcturus’ mRNA Liver Therapeutics Platform On Sept. 23
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today
1 month ago businesswire.com
Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and…
1 month ago benzinga.com
National Beverage Posts Downbeat Q1 Results, Joins Zumiez, Adobe And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures rose, while National Beverage and several stocks fell premarket after disappointing results, led by Zumiez down 15.7%.
1 month ago seekingalpha.com
Arcturus Therapeutics Holdings Inc. (ARCT) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Arcturus Therapeutics Holdings Inc. (ARCT) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
1 month ago defenseworld.net
56,895 Shares in Arcturus Therapeutics Holdings Inc. $ARCT Bought by Hsbc Holdings PLC
Hsbc Holdings PLC acquired a new position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) during the second quarter, according to the company in its most recent 13F filing with the…
1 month ago defenseworld.net
BlackRock Inc. Invests $17.57 Million in Arcturus Therapeutics Holdings Inc. $ARCT
BlackRock Inc. bought a new position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The…
2 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers bioAffinity Technologies (NASDAQ:BIAF) shares rose 43.1% to $6.53 during Tuesday's regular session. The company's market cap stands at $2.7 million. USBC (AMEX:USBC) stock moved upwards by…
2 months ago businesswire.com
Arcturus Therapeutics to Participate in Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and…
2 months ago zacks.com
Arcturus Therapeutics (ARCT) Just Flashed Golden Cross Signal: Do You Buy?
After reaching an important support level, Arcturus Therapeutics Holdings Inc. (ARCT) could be a good stock pick from a technical perspective. ARCT recently experienced a "golden cross" event, which…
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Werewolf Therapeutics (NASDAQ:HOWL) shares increased by 108.1% to $0.9 during Friday's regular session. The market value of their outstanding shares is at $20.9 million. Jupiter Neurosciences…
2 months ago benzinga.com
Elon Musk Says mRNA Has ‘Tremendous’ Potential After Moderna, Merck Cancer Vaccine Breakthrough — MRNA Stock Falls Over 11% in Premarket (UPDATED)
Elon Musk said mRNA could fundamentally change disease treatment, turning medicine into a software problem.
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Tenon Medical (NASDAQ:TNON) stock rose 122.5% to $12.13 during Wednesday's pre-market session. The market value of their outstanding shares is at $3.6 million. As per the news, the Q2…
2 months ago marketbeat.com
Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline
Arcturus Therapeutics NASDAQ: ARCT is positioning its mRNA platform around two rare-disease programs targeting cystic fibrosis and ornithine transcarbamylase deficiency, while its vaccine business is…
2 months ago seekingalpha.com
Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2026 Earnings Call Transcript
Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2026 Earnings Call Transcript
2 months ago zacks.com
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Beats Revenue Estimates
Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to a loss of $0.34 per share a year ago.
2 months ago marketbeat.com
Arcturus Therapeutics Q2 Earnings Call Highlights
Arcturus Therapeutics NASDAQ: ARCT reported progress across its rare-disease pipeline during the second quarter of 2026, completed enrollment and dosing in its Phase II ornithine transcarbamylase…
-
2 months ago benzinga.com
Arcturus Therapeutics Q2 EPS $(0.84) Beats $(1.00) Estimate, Sales $2.959M Miss $3.199M Estimate
Arcturus Therapeutics (NASDAQ:ARCT) reported quarterly losses of $(0.84) per share which beat the analyst consensus estimate of $(1.00) by 16 percent. This is a 147.06 percent decrease over losses of…
2 months ago businesswire.com
Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and…
3 months ago businesswire.com
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on Aug 6, 2026
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and…
3 months ago defenseworld.net
Financial Review: Arcturus Therapeutics (NASDAQ:ARCT) vs. Zenas BioPharma (NASDAQ:ZBIO)
Zenas BioPharma (NASDAQ: ZBIO - Get Free Report) and Arcturus Therapeutics (NASDAQ: ARCT - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare…
-
3 months ago benzinga.com
Arcturus Therapeutics To Present At Canaccord Annual Growth Conference August 11
Webcast link can be found under Investor Relations/Events section of Arcturus’ website.
4 months ago benzinga.com
Arcturus Picks Thermo Fisher To Support Cystic Fibrosis Therapy
Arcturus partners with Thermo Fisher to support Phase 3 development and potential commercialization of ARCT-032 for cystic fibrosis.
4 months ago benzinga.com
This Adobe Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday
Top analysts upgraded Palantir, Silicom, Adobe, and Chevron. See what other analysts think about these stocks. Photo via Shutterstock.
4 months ago benzinga.com
This Honeywell Aerospace Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Wall Street analysts change outlook on top names. Check analyst ratings page for all changes. Consider buying HONA stock - analysts' thoughts.
-
4 months ago benzinga.com
Arcturus Therapeutics Collaborates With Thermo Fisher Scientific To Help Support Phase 3 Development And Potential Commercialization Of ARCT-032, Investigational mRNA Therapy For Cystic Fibrosis
Strategic manufacturing agreement includes Phase 3 clinical supply and commercial manufacturing rightsArcturus Therapeutics Holdings Inc. (("Arcturus", NASDAQ:ARCT), a messenger RNA medicines company…
-
4 months ago benzinga.com
Freedom Broker Initiates Coverage On Arcturus Therapeutics with Buy Rating, Announces Price Target of $27
Freedom Broker analyst Ilya Zubkov initiates coverage on Arcturus Therapeutics (NASDAQ:ARCT) with a Buy rating and announces Price Target of $27.
5 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
5 months ago benzinga.com
Arcturus Therapeutics Q1 EPS $(0.95) Beats $(1.00) Estimate, Sales $2.061M Miss $7.233M Estimate
Arcturus Therapeutics (NASDAQ:ARCT) reported quarterly losses of $(0.95) per share which beat the analyst consensus estimate of $(1.00) by 5 percent. This is a 82.69 percent decrease over losses of…
7 months ago benzinga.com
This Rubrik Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday
Wall Street analysts changed ratings on top stocks. For insights on changes, see analyst ratings page. RBRK stock: buy or not? Analysts weigh in.
7 months ago benzinga.com
This BP Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Friday
Wall Street analysts upgraded top stocks, including Chipotle, ARM, BP, and Solaredge. See what they think about buying BP stock.
7 months ago benzinga.com
This Xponential Fitness Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday
This Xponential Fitness Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday